21.81
price up icon8.35%   1.68
pre-market  Vorhandelsmarkt:  21.76   -0.05   -0.23%
loading
Schlusskurs vom Vortag:
$20.13
Offen:
$20.35
24-Stunden-Volumen:
349.57K
Relative Volume:
1.36
Marktkapitalisierung:
$384.18M
Einnahmen:
$116.88M
Nettoeinkommen (Verlust:
$-25.09M
KGV:
-155.79
EPS:
-0.14
Netto-Cashflow:
$-20.74M
1W Leistung:
+30.68%
1M Leistung:
+27.62%
6M Leistung:
+125.78%
1J Leistung:
+60.37%
1-Tages-Spanne:
Value
$19.58
$21.83
1-Wochen-Bereich:
Value
$17.10
$21.83
52-Wochen-Spanne:
Value
$7.4843
$29.82

Rigel Pharmaceuticals Stock (RIGL) Company Profile

Name
Firmenname
Rigel Pharmaceuticals
Name
Telefon
650-624-1100
Name
Adresse
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
147
Name
Twitter
@rigelpharma
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
RIGL's Discussions on Twitter

Vergleichen Sie RIGL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RIGL
Rigel Pharmaceuticals
21.81 384.18M 116.88M -25.09M -20.74M -0.14
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-04-03 Fortgesetzt Piper Sandler Neutral
2022-06-09 Herabstufung Citigroup Buy → Neutral
2022-06-08 Herabstufung Cantor Fitzgerald Overweight → Neutral
2022-06-08 Herabstufung Piper Sandler Overweight → Neutral
2022-03-23 Eingeleitet B. Riley Securities Neutral
2020-11-09 Herabstufung JP Morgan Overweight → Neutral
2019-11-15 Fortgesetzt Cantor Fitzgerald Overweight
2019-09-26 Fortgesetzt JP Morgan Overweight
2019-03-01 Bestätigt Cantor Fitzgerald Overweight
2018-08-27 Eingeleitet Citigroup Buy
2018-05-02 Bestätigt Cantor Fitzgerald Overweight
2017-12-21 Fortgesetzt Piper Jaffray Overweight
2017-12-15 Eingeleitet Cantor Fitzgerald Overweight
2017-11-06 Fortgesetzt H.C. Wainwright Buy
2017-03-09 Bestätigt H.C. Wainwright Buy
2016-08-31 Bestätigt H.C. Wainwright Buy
2016-08-30 Bestätigt Piper Jaffray Overweight
2016-07-13 Eingeleitet H.C. Wainwright Buy
2016-06-13 Eingeleitet Piper Jaffray Overweight
2016-04-22 Hochstufung JP Morgan Neutral → Overweight
2013-04-08 Bestätigt Stifel Buy
2012-11-29 Eingeleitet UBS Neutral
2012-11-06 Bestätigt Oppenheimer Outperform
2012-03-26 Eingeleitet Canaccord Genuity Hold
2010-12-10 Herabstufung MP Advisors Outperform → Market Perform
Alle ansehen

Rigel Pharmaceuticals Aktie (RIGL) Neueste Nachrichten

pulisher
Jan 21, 2025

JW Pharmaceutical gains approval for immune thrombocytopenia treatment TavalisseCHOSUNBIZ - 조선비즈

Jan 21, 2025
pulisher
Jan 20, 2025

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Sold by Assenagon Asset Management S.A. - MarketBeat

Jan 20, 2025
pulisher
Jan 20, 2025

Long Term Trading Analysis for (RIGL) - Stock Traders Daily

Jan 20, 2025
pulisher
Jan 20, 2025

KFDA approves immune thrombocytopenia treatment Tavalisse from Rigel PharmaceuticalsCHOSUNBIZ - 조선비즈

Jan 20, 2025
pulisher
Jan 20, 2025

Assenagon Asset Management S.A. Sells 30,987 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World

Jan 20, 2025
pulisher
Jan 19, 2025

Barclays PLC Grows Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat

Jan 19, 2025
pulisher
Jan 18, 2025

Short Interest in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Rises By 27.1% - MarketBeat

Jan 18, 2025
pulisher
Jan 18, 2025

Wall Street Analysts Predict a 75.79% Upside in Rigel (RIGL): Here's What You Should Know - MSN

Jan 18, 2025
pulisher
Jan 18, 2025

Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz - MSN

Jan 18, 2025
pulisher
Jan 17, 2025

Rigel (RIGL) Upgraded to Buy: Here's Why - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

Equities Analysts Set Expectations for RIGL Q4 Earnings - MarketBeat

Jan 17, 2025
pulisher
Jan 16, 2025

Rigel Pharmaceuticals Seeks for Acquisitions -January 16, 2025 at 11:15 am EST - Marketscreener.com

Jan 16, 2025
pulisher
Jan 16, 2025

Cantor Fitzgerald Has Positive View of RIGL FY2024 Earnings - MarketBeat

Jan 16, 2025
pulisher
Jan 14, 2025

Rigel Pharmaceuticals' (RIGL) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Jan 14, 2025
pulisher
Jan 13, 2025

Rigel forecasts revenue growth in 2025, reports Q4 sales - Investing.com India

Jan 13, 2025
pulisher
Jan 13, 2025

RIGLRigel Pharmaceuticals Inc. (New) Latest Stock News & Market Updates - StockTitan

Jan 13, 2025
pulisher
Jan 13, 2025

Rigel Pharmaceuticals sets 2025 sales outlook above estimates - MSN

Jan 13, 2025
pulisher
Jan 13, 2025

Rigel forecasts revenue growth in 2025, reports Q4 sales By Investing.com - Investing.com South Africa

Jan 13, 2025
pulisher
Jan 13, 2025

Rigel Provides Business Update and 2025 Outlook - PR Newswire

Jan 13, 2025
pulisher
Jan 13, 2025

Rigel Pharma Revenue Soars as TAVALISSE Hits $100M Sales Milestone, Sets Ambitious 2025 Targets - StockTitan

Jan 13, 2025
pulisher
Jan 09, 2025

(RIGL) Technical Data - Stock Traders Daily

Jan 09, 2025
pulisher
Jan 09, 2025

Rigel announces R289 granted Orphan Drug designation by FDA for MDS - TipRanks

Jan 09, 2025
pulisher
Jan 09, 2025

Rigel Pharmaceuticals Gets FDA Orphan-Drug Designation for R289 - MarketWatch

Jan 09, 2025
pulisher
Jan 09, 2025

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS - PR Newswire

Jan 09, 2025
pulisher
Jan 09, 2025

Rigel's MDS Drug R289 Receives FDA Orphan Drug Status, Boosting Market Exclusivity Potential - StockTitan

Jan 09, 2025
pulisher
Jan 08, 2025

Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Confe - GuruFocus.com

Jan 08, 2025
pulisher
Jan 08, 2025

Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PR Newswire

Jan 08, 2025
pulisher
Jan 08, 2025

Jane Street Group LLC Lowers Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat

Jan 08, 2025
pulisher
Jan 03, 2025

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Malaysian Reserve

Jan 03, 2025
pulisher
Jan 03, 2025

Brokerages Set Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) PT at $36.20 - MarketBeat

Jan 03, 2025
pulisher
Jan 01, 2025

Rigel Pharma expects to complete workforce reduction by Dec 15 - Reuters

Jan 01, 2025
pulisher
Dec 30, 2024

Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents (NASDAQ:RIGL) - Seeking Alpha

Dec 30, 2024
pulisher
Dec 30, 2024

Rigel enrols first participant in Phase Ib/II AML treatment regimen trial - MSN

Dec 30, 2024
pulisher
Dec 26, 2024

Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Pass Above 200 Day Moving AverageShould You Sell? - MarketBeat

Dec 26, 2024
pulisher
Dec 20, 2024

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 28% Price Drop - Simply Wall St

Dec 20, 2024
pulisher
Dec 19, 2024

Rigel to Present at the Jefferies London Healthcare Conference - The Eastern Progress Online

Dec 19, 2024
pulisher
Dec 19, 2024

(RIGL) Trading Signals - Stock Traders Daily

Dec 19, 2024
pulisher
Dec 13, 2024

Rigel Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com Australia

Dec 13, 2024
pulisher
Dec 12, 2024

Recent 26% pullback isn't enough to hurt long-term Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders, they're still up 50% over 1 year - Yahoo Finance

Dec 12, 2024
pulisher
Dec 12, 2024

Thérapeutique Knight annonce l’approbation réglementaire de TAVALISSE® au Mexique - GlobeNewswire Inc.

Dec 12, 2024
pulisher
Dec 12, 2024

Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders are still up 50% over 1 year despite pulling back 26% in the past week - Simply Wall St

Dec 12, 2024
pulisher
Dec 11, 2024

Immune Thrombocytopenia Purpura Market to Expand Significantly by 2034, States DelveInsight Report | Biotest, Argenx, Sanofi, Principia Biopharma, Rigel Pharma, Principia Biopharma, GlaxoSmithKline - The Globe and Mail

Dec 11, 2024
pulisher
Dec 10, 2024

Rigel to Present at the 2024 Cantor Global Healthcare Conference - The Eastern Progress Online

Dec 10, 2024
pulisher
Dec 10, 2024

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition - The Malaysian Reserve

Dec 10, 2024
pulisher
Dec 10, 2024

Rigel Pharmaceuticals (NASDAQ:RIGL) Given "Buy" Rating at HC Wainwright - MarketBeat

Dec 10, 2024
pulisher
Dec 09, 2024

Rigel Pharmaceuticals announces initial data from Phase 1b study of R289 - TipRanks

Dec 09, 2024
pulisher
Dec 09, 2024

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Rating of "Hold" from Analysts - MarketBeat

Dec 09, 2024
pulisher
Dec 09, 2024

Rigel's R289 Shows 40% Response Rate in Blood Cancer Trial, Earns FDA Fast Track Status - StockTitan

Dec 09, 2024

Finanzdaten der Rigel Pharmaceuticals-Aktie (RIGL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
Kapitalisierung:     |  Volumen (24h):